MCID: BRS049
MIFTS: 50

Breast Carcinoma in Situ

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Breast Carcinoma in Situ

MalaCards integrated aliases for Breast Carcinoma in Situ:

Name: Breast Carcinoma in Situ 12 44 15
Carcinoma in Situ of Breast 12 32
Non-Infiltrating Carcinoma of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8791
ICD9CM 34 233.0
MeSH 44 D000071960
SNOMED-CT 67 154636004
ICD10 32 D05 D05.9
UMLS 70 C0154084

Summaries for Breast Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the breast.

MalaCards based summary : Breast Carcinoma in Situ, also known as carcinoma in situ of breast, is related to comedo carcinoma and lobular neoplasia. An important gene associated with Breast Carcinoma in Situ is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Oxybutynin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Breast Carcinoma in Situ

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Sporadic Breast Cancer
Breast Carcinoma in Situ

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 354)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 32.6 TP53 PGR ESR1 ERBB2
2 lobular neoplasia 32.4 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
3 ductal carcinoma in situ 32.4 VEGFA TP53 PGR ESR1 ERBB2 BRCA2
4 in situ carcinoma 31.7 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
5 breast ductal carcinoma 30.9 VEGFC VEGFA TP53 PGR MET KRT19
6 tubular adenocarcinoma 30.6 PGR ESR1 ERBB2
7 mammary paget's disease 30.6 PGR ESR1 ERBB2
8 breast fibroadenoma 30.5 TP53 PGR ESR1 ERBB2 BRCA1
9 female breast cancer 30.4 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
10 breast disease 30.3 VEGFA TP53 PGR KRT19 ESR1 ERBB2
11 ovarian cancer 29.6 VEGFC VEGFA TP53 PGR MET KDR
12 breast cancer 29.3 VEGFC VEGFA TP53 PGR MET KRT19
13 breast apocrine carcinoma in situ 11.6
14 fallopian tube clear cell adenocarcinoma 10.6 BRCA2 BRCA1
15 ovary transitional cell carcinoma 10.5 BRCA2 BRCA1
16 cancerophobia 10.5 BRCA2 BRCA1
17 nosophobia 10.5 BRCA2 BRCA1
18 mutagen sensitivity 10.5 TP53 BRCA2 BRCA1
19 ovarian carcinosarcoma 10.5 TP53 ERBB2 BRCA1
20 septate uterus 10.5 KDR FLT1
21 tetraploidy 10.5 BRCA2 BRCA1
22 gastric papillary adenocarcinoma 10.5 TP53 ERBB2
23 peritoneum cancer 10.5 TP53 BRCA2 BRCA1
24 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 10.5 BRCA2 BRCA1
25 ruvalcaba syndrome 10.5 BRCA2 BRCA1
26 hemifacial spasm 10.5 VEGFA FLT4
27 scirrhous adenocarcinoma 10.5 PGR ERBB2
28 familial ovarian cancer 10.5 ESR1 BRCA2 BRCA1
29 ulcer of lower limbs 10.5 VEGFA IL6 FGF2
30 angiokeratoma of mibelli 10.5 KDR FLT1
31 pediatric angiosarcoma 10.5 VEGFA TP53
32 endosalpingiosis 10.5 PGR BRCA2 BRCA1
33 radiation proctitis 10.5 VEGFA KDR FGF2
34 proctitis 10.5 VEGFA KDR FGF2
35 hereditary site-specific ovarian cancer syndrome 10.5 BRCA2 BRCA1
36 apocrine adenosis of breast 10.5 TP53 PGR ERBB2
37 triple-receptor negative breast cancer 10.5 PGR ERBB2 BRCA2
38 cervical adenocarcinoma 10.5 TP53 ESR1 ERBB2
39 lipid-rich breast carcinoma 10.5 PGR ERBB2
40 osteochondroma 10.5 FGFR1 FGF2 ERBB2
41 breast sarcoma 10.5 TP53 PGR ERBB2
42 pseudopterygium 10.5 KRT19 FGFR1 FGF2
43 decubitus ulcer 10.5 VEGFA IL6 FGF2
44 myasthenic syndrome, congenital, 6, presynaptic 10.5 TP53 BRCA2 BRCA1
45 carcinosarcoma 10.5 TP53 PGR ERBB2
46 bartholin's gland adenoid cystic carcinoma 10.5 PGR ESR1
47 uterine corpus adenosarcoma 10.5 PGR ESR1
48 ovarian clear cell adenocarcinoma 10.5 VEGFA TP53 MET
49 malignant ciliary body melanoma 10.5 KDR FLT1
50 chronic tympanitis 10.5 PGR ESR1

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to Breast Carcinoma in Situ

Symptoms & Phenotypes for Breast Carcinoma in Situ

GenomeRNAi Phenotypes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.66 ESR1 FGFR1 KDR
2 Decreased viability GR00221-A-2 9.66 BRCA1 ESR1 FGFR1 FLT1 FLT4 KDR
3 Decreased viability GR00221-A-3 9.66 BRCA1 KDR
4 Decreased viability GR00221-A-4 9.66 ESR1 KDR
5 Decreased viability GR00249-S 9.66 KDR
6 Decreased viability GR00301-A 9.66 BRCA1
7 Decreased viability GR00342-S-1 9.66 FLT4
8 Decreased viability GR00342-S-2 9.66 FLT4
9 Decreased viability GR00342-S-3 9.66 FLT4
10 Decreased viability GR00386-A-1 9.66 ESR1 FGFR1 FLT4
11 Decreased viability GR00402-S-2 9.66 ESR1
12 Decreased substrate adherent cell growth GR00193-A-1 9.35 MET
13 Decreased substrate adherent cell growth GR00193-A-3 9.35 MET
14 Decreased substrate adherent cell growth GR00193-A-4 9.35 FGFR1 KDR MET
15 Decreased cell migration GR00055-A-1 9.33 FLT1 MET
16 Decreased cell migration GR00055-A-3 9.33 SDC1

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.54 BRCA1 CLDN4 ERBB2 ESR1 FGF2 FGFR1
2 homeostasis/metabolism MP:0005376 10.54 BRCA1 BRCA2 CLDN4 ERBB2 ESR1 FGF2
3 cellular MP:0005384 10.53 BRCA1 BRCA2 CLDN4 ERBB2 ESR1 FGF2
4 mortality/aging MP:0010768 10.47 BRCA1 BRCA2 CLDN4 ERBB2 ESR1 FGF2
5 behavior/neurological MP:0005386 10.46 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
6 growth/size/body region MP:0005378 10.45 BRCA1 BRCA2 CLDN4 ERBB2 ESR1 FGFR1
7 immune system MP:0005387 10.45 BRCA1 BRCA2 ESR1 FGFR1 FLT1 FLT4
8 embryo MP:0005380 10.44 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
9 hematopoietic system MP:0005397 10.41 BRCA1 BRCA2 CLDN4 ESR1 FGF2 FGFR1
10 integument MP:0010771 10.41 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
11 endocrine/exocrine gland MP:0005379 10.4 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6
12 digestive/alimentary MP:0005381 10.38 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
13 nervous system MP:0003631 10.31 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
14 muscle MP:0005369 10.29 BRCA1 ERBB2 ESR1 FGF2 FGFR1 FLT1
15 neoplasm MP:0002006 10.27 BRCA1 BRCA2 ERBB2 ESR1 FGF2 IL6
16 normal MP:0002873 10.24 BRCA1 BRCA2 CLDN4 ERBB2 ESR1 FGFR1
17 limbs/digits/tail MP:0005371 10.22 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6ST
18 liver/biliary system MP:0005370 10.16 ESR1 FLT4 IL6 IL6ST KDR KRT19
19 reproductive system MP:0005389 10.13 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
20 no phenotypic analysis MP:0003012 10.06 ESR1 FGFR1 FLT4 KDR KRT19 MET
21 renal/urinary system MP:0005367 9.92 BRCA1 CLDN4 ESR1 FGFR1 IL6 MET
22 respiratory system MP:0005388 9.81 BRCA1 ERBB2 ESR1 IL6 KDR KRT19
23 skeleton MP:0005390 9.77 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
24 vision/eye MP:0005391 9.32 FGF2 FGFR1 FLT1 IL6 IL6ST KDR

Drugs & Therapeutics for Breast Carcinoma in Situ

Drugs for Breast Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
2
Metformin Approved Phase 3 657-24-9 4091 14219
3
Pembrolizumab Approved Phase 3 1374853-91-4
4
Afimoxifene Investigational Phase 2, Phase 3 68392-35-8
5 Parasympatholytics Phase 3
6 Muscarinic Antagonists Phase 3
7 Neurotransmitter Agents Phase 3
8 Cholinergic Agents Phase 3
9 Mandelic Acids Phase 3
10 Cholinergic Antagonists Phase 3
11 Hypoglycemic Agents Phase 3
12 Hydroxytamoxifen Phase 2, Phase 3
13
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
14
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
15
Epirubicin Approved Phase 2 56420-45-2 41867
16
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
17
Bevacizumab Approved, Investigational Phase 2 216974-75-3
18
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
19
Iodine Approved, Investigational Phase 2 7553-56-2 807
20
Ethanol Approved Phase 2 64-17-5 702
21
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
22
Curcumin Approved, Experimental, Investigational Phase 2 458-37-7 969516
23
Bazedoxifene Approved, Investigational Phase 2 198481-32-2
24
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
25 Omega 3 Fatty Acid Phase 2
26 Antimetabolites Phase 2
27 Angiogenesis Inhibitors Phase 2
28 Narcotics Phase 2
29 Narcotic Antagonists Phase 2
30 Estrogens, Conjugated (USP) Phase 2
31 Tin Fluorides Phase 2
32 Protein Kinase Inhibitors Phase 2
33
Pasireotide Approved Phase 1 396091-73-9 9941444
34
Atorvastatin Approved Phase 1 134523-00-5 60823
35
Bexarotene Approved, Investigational Phase 1 153559-49-0 82146
36
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
37
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
38
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
39
Daunorubicin Approved Phase 1 20830-81-3 30323
40
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
41
Talimogene laherparepvec Approved, Experimental, Investigational Phase 1 1187560-31-1
42
Ipilimumab Approved Phase 1 477202-00-9
43
nivolumab Approved Phase 1 946414-94-4
44
Molgramostim Investigational Phase 1 99283-10-0
45
Pyrazole Experimental Phase 1 288-13-1
46 Anticholesteremic Agents Phase 1
47 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1
48 Lipid Regulating Agents Phase 1
49 Hypolipidemic Agents Phase 1
50 Immunologic Factors Phase 1

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR) Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
2 Optimal Wound Care After Simplex or Modified Radical Mastectomy With or Without Axillary Lymphadenectomy Placement of a Drain Versus the Use of Adaptive Skin Sutures; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
3 A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes Completed NCT02961790 Phase 3 Oxybutynin Chloride
4 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
5 Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer Recruiting NCT03077841 Phase 2, Phase 3
6 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy Recruiting NCT02954874 Phase 3
7 Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women Recruiting NCT01905046 Phase 3 metformin hydrochloride
8 Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial Recruiting NCT04046159 Phase 3 Low-dose tamoxifen
9 A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ Not yet recruiting NCT04570956 Phase 2, Phase 3 Tamoxifen;Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each breast/day;Placebo
10 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
11 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
12 TRI-fraction Radiotherapy Utilized to Minimize Patient Hospital Trips : A Phase II Trial (TRIUMPH-T Trial) Completed NCT02526498 Phase 2
13 A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma Completed NCT01869764 Phase 2 omega-3 fatty acid
14 A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors Completed NCT02150525 Phase 2
15 Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
16 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast. Completed NCT03002766 Phase 2
17 Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Completed NCT02137252 Phase 2 Naltrexone;Sugar Pill
18 Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis Completed NCT02556632 Phase 2 Curcumin-based Gel
19 Phase IIB Pre-Surgical Trial of Oral Tamoxifen Versus Transdermal 4-hydroxytamoxifen in Women With DCIS of the Breast Recruiting NCT02993159 Phase 2 Afimoxifene;Tamoxifen Citrate
20 A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ Recruiting NCT02694809 Phase 2 Conjugated Estrogens/Bazedoxifene
21 NOVEMBER (Novem- (9), BrEast Radiation), A Phase II Trial of a 9 Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer Recruiting NCT03345420 Phase 2
22 Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) Recruiting NCT03979508 Phase 2 Abemaciclib
23 Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation Recruiting NCT01245712 Phase 2
24 A Phase II Study of the Determinants of Transdermal Drug Delivery to the Normal and the Radiated Breast Recruiting NCT04009044 Phase 2 Afimoxifene
25 TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
26 Testing a Scalable Nutrition and Physical Activity Program for Breast Cancer Survivors: A Dose-Finding Pilot Study Recruiting NCT04200482 Phase 2
27 Utilization of Patient Reported Outcomes Generated by Electronic Medical Record and Smart Pill Bottles With Follow up Telehealth Encounters to Improve Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients Recruiting NCT04054557 Phase 2
28 A Phase II Study of Accelerated 3 Fraction Photon and Proton Partial Breast External Beam Radiotherapy and Partial Breast Brachytherapy for Early Invasive and Noninvasive Breast Cancer Active, not recruiting NCT03391388 Phase 2
29 Wide Excision Alone for DCIS-Grades 1 and 2 Active, not recruiting NCT00165256 Phase 2
30 Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy Active, not recruiting NCT02314156 Phase 2 Telapristone Acetate;Telapristone Acetate
31 Alternative Dosing of Exemestane in Postmenopausal Women With Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial Active, not recruiting NCT02598557 Phase 2 Exemestane
32 A Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors Not yet recruiting NCT04290897 Phase 2 Anhydrous Enol-oxaloacetate
33 Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer Terminated NCT01754519 Phase 2
34 EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast Terminated NCT00082667 Phase 2 gefitinib
35 A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer Withdrawn NCT01100489 Phase 2
36 Phase II Trial of CO2RE Laser for Patients With Stage 0-III Hormone Receptor-Positive Breast Cancer on Aromatase Inhibitors With Vulvovaginal Atrophy Withdrawn NCT03666819 Phase 2
37 Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer Completed NCT01077453 Phase 1 letrozole
38 Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial Completed NCT01372644 Phase 1 SOM 230 / Pasireotide
39 A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer Completed NCT00637481 Phase 1 atorvastatin calcium
40 A Phase IB Trial of Neoadjuvant Multi-Epitope HER2 Peptide Vaccine in Patients With HER2-Expressing DCIS Recruiting NCT04144023 Phase 1
41 Assessing the Usability and Workflow Impact of a Mobile-Based Breast Cancer Survivorship Care Plan in the Oncology Practice Recruiting NCT04693338 Phase 1
42 A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer Recruiting NCT03323658 Phase 1 Bexarotene
43 Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Recruiting NCT04081389 Phase 1 Celecoxib;Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Paclitaxel;Rintatolimod
44 Pilot Biomarker Modulation Study of Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer Active, not recruiting NCT02278965 Phase 1 Metformin;Omega-3 fatty acids
45 Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery Active, not recruiting NCT03317405 Phase 1 Endoxifen Hydrochloride
46 Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON) Active, not recruiting NCT01706432 Phase 1
47 A Phase 1 Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Localized Breast Cancer-deleted Active, not recruiting NCT04185311 Phase 1
48 GLACIER: A Study to Investigate the Genetics of LobulAr Carcinoma In Situ in EuRope Unknown status NCT00536718
49 Phase II Study of Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery Unknown status NCT02617082
50 Fast Spectral Imaging Device for Tumor Margin Mapping Completed NCT01107080

Search NIH Clinical Center for Breast Carcinoma in Situ

Cochrane evidence based reviews: breast carcinoma in situ

Genetic Tests for Breast Carcinoma in Situ

Anatomical Context for Breast Carcinoma in Situ

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Carcinoma in Situ:

19
Breast

MalaCards organs/tissues related to Breast Carcinoma in Situ:

40
Breast, Skin, Lymph Node, Liver, Endothelial

Publications for Breast Carcinoma in Situ

Articles related to Breast Carcinoma in Situ:

(show top 50) (show all 162)
# Title Authors PMID Year
1
[MiR-4443 promotes migration and invasion of breast cancer cells by inhibiting PEBP1 expression]. 61
33380387 2020
2
Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study. 61
33148280 2020
3
Perineural and intraneural involvement in ductal carcinoma in-situ of breast: Case report. 61
31543222 2019
4
Ductal carcinoma in situ of breast: update 2019. 61
31472981 2019
5
Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ. 61
30816935 2019
6
MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene. 61
30259272 2019
7
Pure secretory carcinoma in situ: a case report and literature review. 61
31443715 2019
8
Androgen Receptors in Resected Ductal Carcinoma In Situ of Breast: Novel Insights With Possible Implications for Testing and Targeted Endocrine Chemoprevention Trials. 61
29489512 2019
9
"Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y. 61
30875106 2019
10
Sperm Protein Antigen 17 Expression Correlates With Lymph Node Metastasis and Worse Overall Survival in Patients With Breast Cancer. 61
31417875 2019
11
Clinical presentation of ductal carcinoma in situ of breast with intraluminal crystalloids: Radiologic-histologic correlation. 61
30241034 2018
12
Claudin-4 Expression Is Associated With Disease-Free Survival in Breast Carcinoma-in-Situ: Mean Follow-up of 8.2 Years. 61
30025999 2018
13
Sensitivity and specificity of breast cancer ICD-9-CM codes in three Italian administrative healthcare databases: a diagnostic accuracy study. 61
30037866 2018
14
Single-cell heterogeneity in ductal carcinoma in situ of breast. 61
29148540 2018
15
Overtreatment in surgery - does it concern also the patients with ductal breast carcinoma in situ. 61
29513252 2018
16
Risk of death from breast cancer after treatment for ductal carcinoma in situ. 61
28832961 2017
17
Expression of periostin in breast cancer cells. 61
28902360 2017
18
Non-calcified ductal carcinoma in situ of the breast: comparison of diagnostic accuracy of digital breast tomosynthesis, digital mammography, and ultrasonography. 61
27837442 2017
19
Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis. 61
28394473 2017
20
Loss of Tpm4.1 leads to disruption of cell-cell adhesions and invasive behavior in breast epithelial cells via increased Rac1 signaling. 61
28431393 2017
21
Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation. 61
27639877 2017
22
Plasma carotenoids and the risk of premalignant breast disease in women aged 50 and younger: a nested case-control study. 61
28190250 2017
23
Ductal carcinoma in situ of breast: detection and treatment pattern in Hong Kong. 61
27779099 2017
24
Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast. 61
28894698 2017
25
Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. 61
28086982 2017
26
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. 61
28286675 2017
27
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. 61
27926499 2017
28
Differential distribution of immune cells in breast invasive carcinoma vs. breast carcinoma in situ and its significance in interpretation of immune surveillance. 61
31966621 2017
29
[Chinese expert consensus on the diagnosis and treatment of breast carcinoma in situ]. 61
27998472 2016
30
Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling. 61
26876209 2016
31
Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study. 61
27648168 2016
32
Different Biological Action of Oleic Acid in ALDHhigh and ALDHlow Subpopulations Separated from Ductal Carcinoma In Situ of Breast Cancer. 61
27589390 2016
33
Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast. 61
27644608 2016
34
Cancer statistics: Breast cancer in situ. 61
26431342 2015
35
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. 61
26276354 2015
36
Basal cytokeratin phenotypes of myoepithelial cells indicates the origin of ductal carcinomas in situ of the breast. 61
26336082 2015
37
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. 61
26062614 2015
38
Acoustic radiation force impulse elastography for differentiation of malignant and benign breast lesions: a meta-analysis. 61
26131049 2015
39
Context-Dependent Function of Myoepithelial Cells in Breast Morphogenesis and Neoplasia. 61
28680803 2015
40
A prospective cohort study on postoperative radiotherapy with TomoDirect using simultaneous integrated boost technique in early breast cancer. 61
25410791 2014
41
Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma. 61
25109497 2014
42
Armc8 expression was elevated during atypia-to-carcinoma progression and associated with cancer development of breast carcinoma. 61
25119601 2014
43
The CDC42-interacting protein 4 controls epithelial cell cohesion and tumor dissemination. 61
25203208 2014
44
Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens. 61
24678687 2014
45
[The relationship between passive smoking, breast cancer risk and n-acetyltransferase 2 (NAT2)]. 61
24791559 2014
46
[Sentinel lymph node metastasis in patients with ductal breast carcinoma in situ]. 61
25312311 2014
47
Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS. 61
24966968 2014
48
High-resolution 3D micro-CT imaging of breast microcalcifications: a preliminary analysis. 61
24393444 2014
49
Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. 61
23208501 2013
50
Comparison of two breast carcinomas: ductal carcinoma in situ and lobular carcinoma in situ. 61
24147320 2013

Variations for Breast Carcinoma in Situ

Expression for Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for Breast Carcinoma in Situ

Pathways related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.25 VEGFC VEGFA TP53 SDC1 PGR MET
2
Show member pathways
13.91 VEGFC TP53 MET KDR IL6ST IL6
3
Show member pathways
13.89 VEGFC VEGFA TP53 OSM MET KDR
4
Show member pathways
13.75 TP53 OSM MET KDR IL6ST IL6
5
Show member pathways
13.73 VEGFC VEGFA TP53 MET KDR IL6
6
Show member pathways
13.64 VEGFC VEGFA TP53 MET KDR IL6
7
Show member pathways
13.62 VEGFC MET KDR IL6 FLT4 FLT1
8
Show member pathways
13.52 VEGFC TP53 OSM MET KDR IL6
9
Show member pathways
13.45 VEGFA TP53 OSM MET IL6ST IL6
10
Show member pathways
13.42 VEGFC MET KDR IL6 FLT4 FLT1
11
Show member pathways
13.41 VEGFC OSM MET KDR IL6 FLT4
12
Show member pathways
13.37 VEGFC VEGFA MET KDR IL6 FLT4
13
Show member pathways
13.19 VEGFC TP53 MET KDR IL6 FLT4
14
Show member pathways
13.15 VEGFC MET KDR IL6 FLT4 FLT1
15
Show member pathways
13.02 MET KDR FLT4 FLT1 FGFR1 ERBB2
16
Show member pathways
13 VEGFC VEGFA MET KDR FLT4 FLT1
17
Show member pathways
12.86 VEGFC VEGFA MET KDR FLT4 FLT1
18
Show member pathways
12.82 VEGFC MET KDR IL6 FLT4 FLT1
19
Show member pathways
12.8 TP53 MET FGFR1 FGF2 ESR1 ERBB2
20
Show member pathways
12.78 TP53 MET FGFR1 FGF2 ERBB2
21
Show member pathways
12.77 TP53 SDC1 MET ESR1 ERBB2
22 12.77 VEGFC VEGFA TP53 MET KDR FLT4
23
Show member pathways
12.75 VEGFA TP53 MET KDR IL6 FGF2
24
Show member pathways
12.73 VEGFC VEGFA PGR KRT19 ESR1
25
Show member pathways
12.73 TP53 PGR MET FLT4 FGFR1 FGF2
26
Show member pathways
12.64 VEGFC VEGFA TP53 KDR FLT1 FGFR1
27 12.61 VEGFA TP53 MET ERBB2 BRCA1
28
Show member pathways
12.61 TP53 SDC1 MET KDR FLT4 FLT1
29
Show member pathways
12.58 TP53 MET KDR FLT4 FLT1 FGFR1
30
Show member pathways
12.51 VEGFC VEGFA MET KDR FLT4 FLT1
31
Show member pathways
12.5 VEGFC MET KDR IL6 FLT4 FLT1
32
Show member pathways
12.49 VEGFC VEGFA KDR FLT4 FLT1
33
Show member pathways
12.49 VEGFA SDC1 KDR ESR1 BRCA1
34 12.46 VEGFC VEGFA TP53 MET IL6ST IL6
35
Show member pathways
12.4 TP53 SDC1 IL6 FGFR1 FGF2
36
Show member pathways
12.37 TP53 IL6ST IL6 ERBB2
37
Show member pathways
12.36 VEGFA TP53 OSM IL6ST
38
Show member pathways
12.35 TP53 MET KDR IL6ST FLT4 FLT1
39
Show member pathways
12.34 VEGFC TP53 MET KDR IL6 FLT4
40 12.33 TP53 MET IL6 FLT1
41 12.29 VEGFC VEGFA MET KDR FLT4 FLT1
42 12.27 VEGFA TP53 ESR1 BRCA2 BRCA1
43
Show member pathways
12.27 VEGFC VEGFA TP53 OSM MET KDR
44 12.21 VEGFA MET KRT19 KDR IL6 FGF2
45 12.17 VEGFA TP53 SDC1 KDR
46 12.12 VEGFA TP53 OSM IL6 FGF2
47 12.12 VEGFA TP53 SDC1 MET KDR FGFR1
48 12.09 VEGFC MET KDR FLT4 FLT1 FGFR1
49 12.04 VEGFA IL6 FLT1 ERBB2
50
Show member pathways
12.02 VEGFC VEGFA KDR FLT4 FLT1

GO Terms for Breast Carcinoma in Situ

Cellular components related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 SDC1 MET KDR FLT4 FLT1 FGFR1
2 extracellular region GO:0005576 9.73 VEGFC VEGFA SDC1 OSM MET KDR
3 basal plasma membrane GO:0009925 9.5 MET ERBB2 CLDN4
4 receptor complex GO:0043235 9.17 MET KDR IL6ST FLT4 FLT1 FGFR1
5 interleukin-6 receptor complex GO:0005896 9.16 IL6ST IL6

Biological processes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.35 VEGFC VEGFA PGR MET IL6ST IL6
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.27 VEGFA TP53 PGR OSM MET IL6
3 multicellular organism development GO:0007275 10.26 VEGFC VEGFA OSM MET KDR FLT4
4 positive regulation of transcription, DNA-templated GO:0045893 10.19 TP53 IL6 FGF2 ESR1 BRCA2 BRCA1
5 phosphorylation GO:0016310 10.18 MET KDR FLT4 FLT1 FGFR1 ERBB2
6 protein phosphorylation GO:0006468 10.17 MET KDR FLT4 FLT1 FGFR1 ERBB2
7 negative regulation of apoptotic process GO:0043066 10.16 VEGFA TP53 KDR IL6ST IL6 FLT4
8 positive regulation of gene expression GO:0010628 10.15 VEGFA TP53 IL6 FGF2 ERBB2 BRCA1
9 negative regulation of gene expression GO:0010629 10.1 VEGFA TP53 PGR KDR FGF2 ESR1
10 angiogenesis GO:0001525 10.08 VEGFC VEGFA KDR FLT4 FLT1 FGF2
11 cytokine-mediated signaling pathway GO:0019221 10.08 VEGFA TP53 SDC1 OSM IL6ST IL6
12 cell migration GO:0016477 10.07 SDC1 MET KDR FLT1 FGFR1
13 positive regulation of cell migration GO:0030335 10.06 VEGFC VEGFA KDR FLT1 CLDN4
14 positive regulation of protein phosphorylation GO:0001934 10.06 VEGFC VEGFA KDR FLT4 FGF2 ERBB2
15 protein autophosphorylation GO:0046777 10.04 KDR FLT4 FLT1 FGFR1 ERBB2
16 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.02 VEGFA KDR FLT4 FGF2
17 positive regulation of angiogenesis GO:0045766 10 VEGFC VEGFA KDR FLT1 FGF2 BRCA1
18 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.96 VEGFA TP53 OSM IL6
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.96 VEGFA OSM IL6ST IL6
20 positive regulation of endothelial cell migration GO:0010595 9.95 VEGFA KDR FLT4 FGF2
21 positive regulation of endothelial cell proliferation GO:0001938 9.95 VEGFC VEGFA KDR FLT4 FGF2
22 peptidyl-tyrosine phosphorylation GO:0018108 9.95 MET KDR FLT4 FLT1 FGFR1 ERBB2
23 positive regulation of epithelial cell proliferation GO:0050679 9.93 VEGFC VEGFA FGF2 ERBB2
24 hematopoietic progenitor cell differentiation GO:0002244 9.93 TP53 KDR FLT4 FLT1
25 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.93 MET KDR FLT4 FLT1 FGFR1 ERBB2
26 positive regulation of cell division GO:0051781 9.91 VEGFC VEGFA OSM FGF2
27 positive chemotaxis GO:0050918 9.91 VEGFC VEGFA MET FGF2
28 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.91 VEGFC VEGFA KDR FLT4 FLT1
29 double-strand break repair GO:0006302 9.89 TP53 BRCA2 BRCA1
30 response to estrogen GO:0043627 9.89 KRT19 ESR1 BRCA1
31 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.89 VEGFA KDR FLT4 FLT1
32 positive regulation of MAP kinase activity GO:0043406 9.89 VEGFA FLT1 FGFR1 FGF2 ERBB2
33 positive regulation of vascular endothelial growth factor production GO:0010575 9.87 IL6ST IL6 FLT4 BRCA1
34 positive regulation of protein kinase B signaling GO:0051897 9.87 VEGFA OSM MET FGFR1 FGF2 ESR1
35 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.86 VEGFA KDR FGF2
36 regulation of angiogenesis GO:0045765 9.86 IL6 FGF2 ERBB2
37 sprouting angiogenesis GO:0002040 9.85 VEGFC VEGFA FLT4
38 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.85 VEGFA OSM KDR FLT1 FGFR1 FGF2
39 cell migration involved in sprouting angiogenesis GO:0002042 9.83 VEGFA KDR FGF2
40 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.83 TP53 BRCA2 BRCA1
41 positive regulation of blood vessel endothelial cell migration GO:0043536 9.83 VEGFC VEGFA KDR FGFR1 FGF2
42 positive regulation of acute inflammatory response GO:0002675 9.81 OSM IL6ST IL6
43 chordate embryonic development GO:0043009 9.75 FGFR1 BRCA2 BRCA1
44 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.73 TP53 ESR1
45 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.73 TP53 ESR1
46 intracellular steroid hormone receptor signaling pathway GO:0030518 9.73 PGR ESR1
47 positive regulation of endothelial cell chemotaxis GO:2001028 9.73 MET FGF2
48 positive regulation of kinase activity GO:0033674 9.73 MET KDR FLT4 FLT1 FGFR1 ERBB2
49 positive regulation of protein kinase C signaling GO:0090037 9.72 VEGFA FLT4
50 vascular wound healing GO:0061042 9.72 VEGFA KDR

Molecular functions related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.46 VEGFC VEGFA TP53 SDC1 PGR OSM
2 kinase activity GO:0016301 9.99 MET KDR FLT4 FLT1 FGFR1 ERBB2
3 protein kinase activity GO:0004672 9.91 MET KDR FLT4 FLT1 FGFR1 ERBB2
4 cytokine activity GO:0005125 9.85 VEGFA OSM IL6 FGF2
5 growth factor activity GO:0008083 9.77 VEGFC VEGFA OSM IL6 FGF2
6 protein tyrosine kinase activity GO:0004713 9.73 MET KDR FLT4 FLT1 FGFR1 ERBB2
7 protein phosphatase binding GO:0019903 9.71 TP53 MET FLT4 ERBB2
8 chemoattractant activity GO:0042056 9.65 VEGFC VEGFA FGF2
9 growth factor binding GO:0019838 9.55 KDR IL6ST FLT4 FLT1 ERBB2
10 interleukin-6 receptor binding GO:0005138 9.54 IL6ST IL6
11 vascular endothelial growth factor receptor binding GO:0005172 9.52 VEGFC VEGFA
12 vascular endothelial growth factor-activated receptor activity GO:0005021 9.5 KDR FLT4 FLT1
13 receptor-receptor interaction GO:0090722 9.49 FGFR1 FGF2
14 identical protein binding GO:0042802 9.47 VEGFA TP53 SDC1 PGR MET KDR
15 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 MET KDR FLT4 FLT1 FGFR1 ERBB2

Sources for Breast Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....